vaccine efficacy
ongoing Phase
Filo prime-boost vaccine regimen
prophylactic vaccine regimen
Filo vaccine
Prophylactic Ebola Vaccine
efficacy data
randomised trial
high quality phase
immunogenicity data
safety data
final trial design
trial results
controlled trial
Clinical trials
proposed heterologous prime-boost regimen of Ad26
o	EBOVAC1
recent Ebola epidemic
novel prime
house data
funded EBOLA
efficacy assumptions
EBOVAC1 project
EBOVAC1 objectives
IMI2 Action - EBOVAC1
substantial immunogenicity
animal immunogenicity
robust safety
initial safety
effectiveness
Ebola-unaffected African countries
Ebola Virus Disease
solid data package
short term efficacy
boost vaccination strategy
Health Agencies
fatal EVD
original design
relevant health authorities
clinical development plan
MVA-BN
licensure requirements
different time intervals
ZEBOV
affected countries
cluster randomized design
preclinical studies
final sample size
final dosage schedule
decline
subjects
urgent public health need
absence of sufficient EVD cases
low EVD incidence rates
IMI2 Action EBOVAC2
information assets
accelerated licensure approval pathway
regulatory requirements
different sequences
immune response
EBOVAC programme
Expanded Programme
shortest schedule
information repository centre
overall aim
split
UK
gold standard approach
evaluation
optimal sequence
humans
association
protection
potential
possibility
consultation
non-human primates
multiple sites
WP4
modelling exercises
larger numbers
candidate vaccines
confirmation
individuals
country
year
projects
EU
adults
Sierra Leone
main objective
Immunization
flare
interactions
children
view
separate teams
summer
event
course